Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: Provided is a novel JAK-specific inhibitor compound and a method for preparing the same. The compound of the provided can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases. In particular, due to its high selectivity for JAK1, the compound of the provided can exhibit better therapeutic effects on inflammatory diseases and autoimmune diseases at a low dose and with fewer side effects and can be expected to be effective in preventing and treating liver fibrosis.

Abstract: The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases.

Abstract: The present invention relates to a dried seaweed snack and a method for preparing the same.

Abstract: A cone-shaped edible container according to the present invention comprises: an edible outer layer; an edible inner layer; a first edible adhesive layer disposed between the outer layer and the inner layer to bond the outer layer and the inner layer together; and a second adhesive layer for maintaining the outer layer and the inner layer to be in the shape of a cone, wherein at least some regions of the edible container have a first cross-section structure in which the inner layer, the first adhesive layer, and the outer layer are sequentially laminated in a direction from the inside toward the outside, and have a second cross-section structure in which the inner layer, the first adhesive layer, the outer layer, the second adhesive layer, the inner layer, the first adhesive layer, and the outer layer are sequentially laminated in the direction from the inside toward the outside.

Abstract: A cone-shaped edible container according to the present invention comprises: an edible outer shell, an edible inner shell, and an edible first adhesive layer provided between the outer shell and the inner shell to adhere the outer shell and the inner shell to each other. The outer shell and the inner shell are rolled into a cone shape in a state of being adhered to each other so as to have a basic structure of a cone shape. The outer shell forms the outermost side of the basic structure, and the inner shell has a stronger rigidity than the outer shell. Thus, assuming a cone-shaped structure implemented only by the outer shell, even if an external force of a magnitude capable of breaking the assumed structure is applied to the basic structure, the basic structure is maintained.

Abstract: Provided are a cleaning device and a method for driving the cleaning device which cleans a wafer after chemical mechanical polishing. The cleaning device includes a cleaning modules and a running beam, the running beam including a first blade and a second blade to insert or remove the wafer with respect to one of the cleaning modules in a second direction, the first blade and the second blade being fixed to the running beam and movable in the second direction, and the cleaning modules including an input module, a megasonic module, a first brush module, a second brush module and a drying module. The driving method includes performing an operation of inserting or removing the wafer in the second direction using the first blade in a first area; and performing an operation of inserting or removing the wafer in the second direction using the second blade in a second area.

Abstract: Provided are a cleaning device and a method for driving the cleaning device which cleans a wafer after chemical mechanical polishing. The cleaning device includes a cleaning modules and a running beam, the running beam including a first blade and a second blade to insert or remove the wafer with respect to one of the cleaning modules in a second direction, the first blade and the second blade being fixed to the running beam and movable in the second direction, and the cleaning modules including an input module, a megasonic module, a first brush module, a second brush module and a drying module. The driving method includes performing an operation of inserting or removing the wafer in the second direction using the first blade in a first area; and performing an operation of inserting or removing the wafer in the second direction using the second blade in a second area.

Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.

Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.